Annual report pursuant to Section 13 and 15(d)

STATEMENTS OF OPERATIONS

v3.19.1
STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenue:      
Total revenue $ 38,419 $ 51,741 $ 59,731
Operating expenses      
Research and development 54,262 54,639 43,550
General and administrative 21,380 16,374 14,817
Total operating expenses 75,642 71,013 58,367
(Loss) income from operations (37,223) (19,272) 1,364
Interest income 1,616 273 251
Interest expense (1,623) (612) 0
Other income (expense), net 1,913 (77) 87
Net (loss) income $ (35,317) $ (19,688) $ 1,702
Net (loss) income per share, attributable to common stockholders, basic and diluted $ (6.13) $ (43.95) $ 0
Weighted-average shares used in computing net (loss) income per share attributable to common stockholders 5,758,875 447,946 407,735
Collaboration Revenue      
Revenue:      
Total revenue [1] $ 32,387 $ 51,741 $ 59,731
Other Revenue      
Revenue:      
Total revenue [1] $ 6,032 $ 0 $ 0
[1] Includes $5.0 million of collaboration revenue and $3.9 million of other revenue from Celgene as related party revenue. Celgene was a related party through September 30, 2018 as it held more than 10% of our common stock for the periods presented until the closing of our IPO.